期刊文献+

4-(1'-哌嗪基)喹啉化合物的合成与分子动力学模拟研究 被引量:1

Synthesis and Molecular Dynamics Simulation of 4-( piperazin-1-yl) Quinolines
下载PDF
导出
摘要 分别以7-氟-4-氯喹啉(化合物1)及7-甲氧基-4-氯喹啉(化合物2)为原料合成7-氟-4-(1'-哌嗪基)喹啉(化合物3)和7-甲氧基-4-(1'-哌嗪基)喹啉(化合物4),化合物结构以ESI-MS确证.将化合物3和化合物4分别与HER1、HER2蛋白形成的复合物进行分子动力学模拟,结果显示:化合物3与HER1的亲和力和化合物4与HER1的亲和力相似;化合物4与HER2的亲和力大于化合物3与HER2的亲和力;目标化合物与蛋白氨基酸残基形成氢键不是亲和力大小的决定性因素. 7-fluoro-4-( piperazin-1-yl) quinolone 3 and 7-methoxy-4-( piperazin-1-yl) quinoline 4 were synthesized from 7-fluoro-4-chloroquinoline 1 and 7-methoxy-4-chloroquinoline 2, respectively and their structures were confirmed by ESI-MS. The molecular dynamics simulation of complex of 3 or 4 with HER1 and HER2 protein were performed. The main results showed that the binding affinity of 3 to HER1 was similar to that of 4 to HER1; the binding affinity of 4 to HER2 was stronger than that of 3 to HER2.The hydrogen bonds were not a decisive factor for affinity.
出处 《沈阳化工大学学报》 CAS 2016年第3期223-226,共4页 Journal of Shenyang University of Chemical Technology
基金 辽宁省教育厅科学研究一般项目(L2013171) 辽宁省大学生创新创业训练计划项目(201310149042)
关键词 7-氟-4-(1'-哌嗪基)喹啉 7-甲氧基-4-(1'-哌嗪基)喹啉 酪氨酸激酶抑制剂 7-fluoro-4-(piperazin-1-yl) quinoline 7-methoxy-4-(piperazin-1-yl) quinoline tyrosine kinase inhibitor
  • 相关文献

参考文献4

二级参考文献131

  • 1吴一龙.肺癌分子靶向治疗的个体化[J].循证医学,2004,4(2):67-68. 被引量:9
  • 2Talpaz M,Shah NP,Kantarjian H,菅鑫妍.Dasatinib用于治疗对伊马替尼耐药的Ph染色体阳性白血病[J].中国处方药,2006,5(8):60-60. 被引量:12
  • 3BIANCO R, MELISI D, CIARDIELLO F, et al. Key cancer cell signal transduction pathways as therapeu- tic targets [ J ]. Eur J Cancer, 2006, 42 ( 3 ) :290 - 294.
  • 4BURRIS H A, HURWITZ H I, DEES E C, et al. Phase I safety,pharmacokinetics, and clinical activi- ty study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas[ J]. J Clin Oncol, 2005,23 ( 23 ) : 5305 - 5313.
  • 5GUNBY R H, SALA E, TARTARIC J, et al. Oncogenie fusion tyrosine kinases as molecular targets for anti-cancer therapy [ J ]. Anticancer Agents Med Chem,2007,7(6) :594 - 611.
  • 6SHARMA P S, SHARMA R, TYAGI T. Receptor tyrosine kinase inhibitors as potent weapons in war against cancers [ J]. Curr Pharm Design, 2009, 15 (7) :758 -776.
  • 7HUANG H, JIA Q, MA J G, et al. Discovering novel quercetin-3-O-amino acid-esters as a new class of Src tyrosine kinase inhibitors [ J ]. Eur J Med Chem, 2009,44( 5 ) 1982 - 1988.
  • 8LIN L G, XIE H, LI H L, et al. Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening[J]. J Med Chem,2008,51 (15) :4419 - 4429.
  • 9GULLO G, BETHO D, TORRI V, et al. Level of HER2 / neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer [J]. Invest New Drugs,2009,27(2) 179 - 183.
  • 10ROSSI A, BRIA E, MAIONE P, et al. The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the Ixeatment of advanced non-smaU cell lung cancer[ J ]. Rev Recent Clin Tri- als,2008,3(3) :217 -227.

共引文献60

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部